Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

计划入组 140 人 · 首次发布于 2021 年 5 月 5 日

Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression

首次发布于 2022 年 8 月 23 日

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

计划入组 23 人 · 首次发布于 2020 年 4 月 16 日

tri-specific anti-Her1/Her3 Zybody

anti-HER2/HER3 dendritic cell vaccine

Ther4

Herc Holdings

HERA BIOTECH, INC.

United States

HERZ PHARMACEUTICAL TECHNOLOGY PTY LTD

Australia

Eribulin-Pyrotinib Combination Shows Promise in Trastuzumab-Resistant HER2+ Breast Cancer

NERLYNX Launches in Thailand as New HER2+ Breast Cancer Treatment Option

Roche Canada and pCPA Complete Negotiations for Perjeta in Neoadjuvant HER2-Positive Early Breast Cancer